Agreements, Partnerships, and Collaborations were Key Growth Strategies Adopted by Leading Market Players in the Global Preimplantation Genetic Testing Market
The global preimplantation genetic testing market is expected to grow at a CAGR of 10.0% between 2017 and 2022. Factors driving the growth of this market include the growing rate of infertility across the world and increasing public-private investments in the field of preimplantation genetic testing among others.
Illumina, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), and SciGene Corporation (U.S.) are some of the major manufacturers in this market; whereas, Beijing Genomics Institute (BGI) (China), Good Start Genetics (U.S.), CombiMatrix Corporation (U.S.), Genea Limited (Australia), Invicta Genetics (Poland), and Progenesis (U.S.) are some of the major service providers.
Analysis of the market developments between 2014 and 2017 (January) show that agreements, partnerships, and collaborations were the most widely adopted growth strategies by players in the market. Players adopted these strategies to strengthen their market position by collaborating to develop and provide technologically advanced products to its customer base. For instance, in June 2016, the Global Fertility Alliance pioneered by Genea (Australia), Merck (U.S.), and Illumina Inc. (U.S.) collaborated with two new members, namely, ZEISS (Germany) and Hamilton Thorne Ltd. (U.S.) to improve innovation and progress in the field of fertility treatment. Another strategy adopted by market players are product launches.
Illumina, Inc. (U.S.) held the leading position in the global preimplantation genetic testing market in 2016. The company has been focusing on agreements, partnerships, and product launches to maintain this position in the market. In 2014, it introduced VeriSeq PGS, NextSeq 500 System, and HiSeq X Ten in the market, which enabled it to garner a high share. The company has a strong global presence with more than 54% of its revenue generated from the U.S. and more than 23% from the European region.
In 2016, Thermo Fisher Scientific Inc. (U.S.) acquired Life Technologies Corporation, a biotechnology company with more than 50,000 products and customers in 160 countries, and established a segment called Life Science Solutions. Through this acquisition, the company entered the highly consolidated preimplantation genetic diagnosis and screening market. Life Technologies acquired Ion Torrent in 2010, which added Ion PGM and Proton to its portfolio. Thermo Fisher Scientific also provides sequencing reagents and consumables along with services. The company has a strong global presence with a well-established supply chain that helped it to garner a prominent share in the preimplantation genetic diagnosis and screening market in 2016. It also aspires to develop unique next-generation sequencing and bioinformatics platforms for researchers to support and enhance genetic construction, design, sequencing, and synthesis.
Related Reports:
Preimplantation Genetic Testing Market by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022
Contact:
Mr. Rohan
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
